RecruitingPhase 3NCT05606614

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

Studying Rett syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taysha Gene Therapies, Inc.
Principal Investigator
Medical Monitor, M.D.
Taysha Gene Therapies
Intervention
TSHA-102(genetic)
Enrollment
15 enrolled
Eligibility
6-21 years · FEMALE
Timeline
20232031

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05606614 on ClinicalTrials.gov

Other trials for Rett syndrome

Additional recruiting or active studies for the same condition.

See all trials for Rett syndrome

← Back to all trials